New York, NY -- (SBWIRE) -- 02/01/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Zoetis Inc (NYSE:ZTS), Celgene Corporation (NASDAQ:CELG), Amgen, Inc. (NASDAQ:AMGN), Galena Biopharma Inc (NASDAQ:GALE)
Zoetis Inc (NYSE:ZTS) declined -1.01%, trading on 5.30 million shares, to end the trade at $30.36. The stock changed hands in a range of $30.07 to $30.54, bringing its market capitalization to about $30.36 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $28.81 and was moved to the maximum level of $35.42. Zoetis Inc, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The primary livestock species are cattle (both beef and dairy), swine, poultry, sheep and fish, and the primary companion animal species are dogs, cats and horses.
Has YGE Found The Bottom And Ready To Gain Momentum? Find Out Here
Celgene Corporation (NASDAQ:CELG) declined -1.33%, to complete the trading session at $151.93, with a total volume of 5.22 million shares. The stock, on average, trades on a volume of 2.97 million shares. It floated in a range of $147.83 to $153.77 during the last trading session, with a beta value of 0.90. Its market capitalization now moved to about $62.61 billion. In the past 52 weeks, the share price has not declined below $96.78 and above $174.66. Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market.
Why Should Investors Buy CELG After the Recent Fall? Just Go Here and Find Out
Amgen, Inc. (NASDAQ:AMGN) recorded a fall of -1.60% and was in a range of $118.10-$120.21 before closing at $118.95. The stock completed the day with a total volume of 4.94 million shares, versus an average volume of 3.23 million shares. The share price hit its 52-week low of $82.92 and $124.46 was the best price. Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses.
Will AMGN Bounce Back After yesterday’s Sharp Sell off? Find Out Here
Galena Biopharma Inc (NASDAQ:GALE) declined -2.59% yesterday, bringing its market capitalization around $554.60 million. The share price, after opening at $5.29, made a high of $5.48 and hovered above $5.15 to end the day at $5.27. The total number of shares that changed hands during the session was 4.87 million shares, as compared to average trading volume of 8.96 million shares. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.
Is it the Right to Grab GALE after the Recent Slump? Get Free Trend Analysis Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)